A new once-daily weight-loss pill has proven more effective than the leading oral semaglutide — the pill version of Ozempic and Wegovy — in a major clinical trial, offering a potential game-changer in the rapidly expanding oral weight-loss drug market.

The drug, orforglipron, developed by Eli Lilly, belongs to a new category called small-molecule GLP-1 drugs. Unlike semaglutide — a peptide drug that closely resembles the natural GLP-1 hormone — orforglipron is a synthetic chemical compound small enough to be absorbed directly through the gut wall.

This gives it two major advantages: it costs less to manufacture, and it doesn't require refrigeration or special timing with meals. Patients don't need to take it on an empty stomach or wait 30 minutes before eating, as required with oral semaglutide.

The Trial Results

The 52-week Phase 3 trial involved 1,698 adults with type 2 diabetes across six countries. From a baseline average HbA1c of 8.3%, orforglipron reduced blood sugar by 1.71–1.91% — significantly outperforming oral semaglutide's 1.47% reduction.

Weight loss was also superior: orforglipron patients lost an average of 6.1–8.2 kg compared to 5.3 kg for semaglutide. Injectables like Wegovy have shown similar weight loss figures, though no head-to-head trial has directly compared orforglipron with injectable GLP-1s.

The Tolerability Trade-off

The main caveat: gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) were more common with orforglipron — 59% of participants reported them, versus 37–45% with semaglutide. About 10% of orforglipron users discontinued treatment due to side effects, compared to 4–5% for semaglutide.

Researchers attribute this to the more prominent daily peak drug concentrations with orforglipron. Whether tolerability will limit its market impact remains to be seen.

Global Access Implications

As a small-molecule drug, orforglipron is cheaper and simpler to manufacture than peptide-based drugs. And like oral semaglutide, it requires no refrigeration — a critical advantage for expanding access in low- and middle-income countries where cold-chain infrastructure is unreliable.

Orforglipron is still undergoing trials in patients with obesity without diabetes. If approved, it could become one of semaglutide's most credible challengers in the multi-billion-dollar weight-loss market.

Sources